Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

The Human Immunodeficiency Virus Pipeline market research report provides a comprehensive overview on the therapeutics under development for Human Immunodeficiency Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus and features dormant and discontinued projects.

Key Targets in the Human Immunodeficiency Virus Pipeline Drugs Market

In the HIV pipeline drugs market the key targets are Reverse Transcriptase, Surface Protein gp12, Gag, HIV 1 Integrase, Glycoprotein 41, T Cell Surface Glycoprotein CD4, HIV 1 Retropepsin, P27, Pol Polyprotein, Capsid Protein, and Glycoprotein 140.

Human Immunodeficiency Virus Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Human Immunodeficiency Virus Pipeline Drugs Market

Reverse Transcriptase Inhibitor has the highest number of pipeline products followed by Surface Protein gp12 Inhibitor, HIV 1 Integrase Inhibitor, Glycoprotein 41 Inhibitor, T Cell Surface Glycoprotein CD4 Inhibitor, HIV 1 Retropepsin Inhibitor, Capsid Protein Inhibitor, HIV Integrase Inhibitor, C-C Chemokine Receptor Type 5 Antagonist, and Gag Inhibitor.

Human Immunodeficiency Virus Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the HIV pipeline drugs market are Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Topical, Vaginal, Intradermal, Rectal, and Nasal. Oral has the maximum number of pipeline products.

Human Immunodeficiency Virus Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Human Immunodeficiency Virus Pipeline Drugs Market

The key molecule types in the HIV pipeline drugs market are Small Molecule, Monoclonal Antibody, Subunit Vaccine, Recombinant Vector Vaccine, Gene-Modified Cell Therapy, Synthetic Peptide, DNA Vaccine, Vaccine, Cell Therapy, and mRNA Vaccine.

Human Immunodeficiency Virus Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Human Immunodeficiency Virus Pipeline Drugs Market

The major companies in the HIV pipeline drugs market are Gilead Sciences Inc, ViiV Healthcare UK Ltd, Merck & Co Inc, Viriom Inc, Aphios Corp, Enochian Biosciences Inc, Statera Biopharma Inc, Johnson & Johnson, OyaGen Inc, and TaiMed Biologics Inc.

Human Immunodeficiency Virus Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus
• The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Human Immunodeficiency Virus therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Human Immunodeficiency Virus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Human Immunodeficiency Virus

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.